Summary
The pharmacokinetics of a single 400 mg oral dose of valnoctamide (VCD) has been investigated in seven healthy, adult, male volunteers. VCD was not biotransformed rapidly to its corresponding acid valnoctic acid (VCA), unlike its isomer valpromide (VPD). It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h. Throughout the study, only low plasma levels of VCA could be detected. Thus, unlike VPD, which is a prodrug of the corresponding acid, (valproic acid, VPA). VCD appears to act as a drug in its own right, and it does not undergo similar hydrolysis. The pharmacokinetic difference may account for the different pharmacological activities of the two isomers.
Similar content being viewed by others
References
Stepansky W (1960) A clinical study in the use of valmethamide, an anxiety reducing drug. Curr Ther Res 2: 144–149
Reynolds JEF (1982) Martindale — the extra pharmacopea, 28th edn. Pharmaceutical Press, London, p 1563
The Merck Index, 10th ed (1983) Merck, Rahway, NJ, USA, pp 9715
Chambon JP, Perio A (1980) Valnoctamide: pharmacological data suggesting an antiepileptic activity. Neurosci Lett [Suppl] 5: S327-S327
Haj-Yehia A, Bialer M (1988) Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 77: 831–834
Bialer M, Rubinstein A, Raz I, Abramsky O (1984) Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol 27: 501–503
Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O (1985) A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int J Pharm 23: 25–33
Pisani F and De Perri R (1980) Some clinical pharmacological aspects of N-dipropylacetamide. Ital J Neurol Sci 4: 245–249
Pisani F, Fazio A, Oteri G, Di Perri R (1981) Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropyl-acetamide. Ther Drug Monit 3: 297–301
Levy RH (1984) Valproate, modern perspectives. Epilepsia 25 [Suppl 1]
Bialer M, Hoch B (1985) Rapid gas chromatographic assay for monitoring valnoctamide. J Chromatogr Biomed Applic 337: 408–411
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd ed. Dekker, New York, pp 445–449
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd ed. Dekker, New York, pp 409–417
Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 574–588
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic clearance. Clin Pharmacol Ther 18: 377–390
Yamaoka K (1986) “Methods for pharmacokinetic analysis for personal computer”, 2nd edn. Nanko-D Ltd., Tokyo, pp 145–175
Haj-Yehia A and Bialer M (1989) Structure pharmacokinetic relationships of a series of valpromide derivatives with antiepileptic activity. Pharm Res 6: 683–687
Lambert PA (1984) Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okama T, Muller AA (eds) Anticonvulsants in Affective Disorders. Excerpta Medica, Amsterdam, pp 33–44
Emrich HM (1987) Anti-Epileptic Agents. II. Diphenylhydantoin, Dipropylacetamide, Valproate and Progabide. In: Johnson FN (ed) Lithium combination treatment. Karger, Basel, pp 156–163
Lambert PA, Venaud G (1987) Utilization du valpromide en therapeutique psychiatrique. L' Encéphale 13: 367–373
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bialer, M., Haj-Yehia, A., Barzaghi, N. et al. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 38, 289–291 (1990). https://doi.org/10.1007/BF00315032
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315032